Member Info for Laura2022

Therefore can sell about x 2 what you can buy (£3k ish only know ask )

Now offering for 455,000 at 2.7p

Not much on ask 2.8p

They are offering 2.71p (nearly the ask ) for 400,000

This looks primed

Scdn

I filtered JJ this week

Another time waster

These people never actually pick a winning stock if yiu notice !!

There will be twists and turns and I'm patiently adding at 2.7-3.3p

Now have 425,000 shares

Lest we forget 3mths jaari888 was promoting TCF which then had a a 90% diluted fund raise and he went silent

Yes Trench

After 3mths jaari and another user both unusually turn up in the same 48hr period

Jaaari is Thiopia on ADFVN and also linked to some less than savoury people on Telwgram

As for sushi , I filtered his 2mths ago , he promoted EME which had its 5th placing in 5mths and also said WG would go to 80p and now WG Is suspended

It's not only the 4th new contract in a sheet space but there are potentially another 4 -5 to come plus 91 leads on other projects already being discussed *see March presentation" also it's yet again with a NEW client and also a NEW area of medicine, the scope for PYC A.I/ Virtual Tumour/ modelling goes way beyond just oncology now

Totally agree

If Troutisout1 hadn't spent 80% of his time on PYC last 8 weeks it would been great

Gluck FAB ers

Personalised dosing app is also at "final sprint" ad pet March update

This and the one with NHS/Beyond Blood could be huge ( see KingHomer J posts on this BB)

They've burnt nearly £800k a month for 4mths

It's not good

Reece

It's the cumulative affect , PYC will be making revenues of nearly half their market cap

Maybe stick to your stuff then

Yes Merck MSA have proved PYC with almost £300-500k revenues per annum for last 8yrs or so

So MSA can be very good

Boggers

There's no way of dressing this up, my fears have been realised

Dr Peter Sargent, CEO of Physiomics, commented:

"We're delighted to have been selected to support the clinical development of this important programme. This contract award not only represents a new client relationship - the third new client in two months - but also is a reflection of our strategy to broaden our services into new therapeutic areas, being our first project in rheumatoid arthritis.

MSAs could be really significant moment (master agreement)

This could be massive!!

The Company has also put in place a Master Service Agreement with the client to define and agree broad commercial terms in relation to envisaged further potential projects in the future.

That's the the 4th out of 9 debull

Hope that reassures you now

Have you watched the March presentation,

is pleased to announce a contract award with a new UK client.

The project will involve the application of population Pharmacokinetic (PK) modelling techniques using Phase 1 data to inform the Phase 2 study of a small molecule designed to treat rheumatoid arthritis. The project, valued at £67,500, is expected to complete within the next three months and will be the Company's first rheumatoid arthritis project as well as one of the later development stage projects delivered to date.

The Company has also put in place a Master Service Agreement with the client to define and agree broad commercial terms in relation to envisaged further potential projects in the future.

These new poster were far too bullish

Belluscura remains committed to achieving profitability. The principal constraint towards achieving this is access to sufficient working capital to fund bulk orders of completed goods, as bulk ordering is a key factor in significantly reducing the unit cost of goods sold.

 

To address this, the Company has initiated a strategic review, which will evaluate a range of options to substantially strengthen its capital position, including potential strategic investment, partnerships, alternative funding structures and other corporate initiatives. The review is aimed at supporting both the Company's short-term cash requirements and its longer-term growth and accelerating its path to sustainable profitability.

 

As at 30 April 2025, the Company's cash balance was $1.00m and its working capital bank debt balance stood at $0.79m.

 

There can be no certainty that the strategic review will result in any specific outcomes, and the Company will provide further updates as appropriate.

 

For the avoidance of doubt, the strategic review is not for the purposes of soliciting offers for the Company pursuant to the City Code on Takeovers and Mergers

Wadagora

If it's who I think it is in the green box there is know telling of what he says/does is real

Bit no doubt he'll slip in CIZ into his posts lol

Essentially FAB have under performed compared to the bullishness of early 2025 and raised money when they suggested they wouldn't, currently below placing price, warned on 2025/26 revenues/headwinds

But you seem to brush this off yet go to PYC slating various things last 8 weeks while claiming to hold

You're a busted flush

Night